Berberine, Zinc, and Quercetin in the Context of Rising Consumer Interest in Natural GLP-1 Support and Non-Prescription Metabolic Wellness Orlando, Florida, Jan
Medical Hypotheses, 68 (5), 1026-1034
2023, with ~33% of commercial lives covered as of the end of Jan
Roughly 50% of states cover GLP-1 medications for obesity, but many require prior authorization, a type 2 diabetes diagnosis, or BMI above 35 kg/m
Prevention and early detection are viewed as opportunities that could lead to substantial gains in PDAC-related outcomes
Assessing Candidacy for Weight Loss Treatment Adults in Killeen with a BMI of 30 or greater, or 27 or greater with conditions like high blood pressure, high cholesterol, cardiovascular disease, or sleep apnea, may be ideal candidates for medical weight loss